The short version
Just 2 companies supply this market — thin enough that a single exit would be felt immediately.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Orphenadrine Citrate, Aspirin and Caffeine
Orphenadrine Citrate, Aspirin and Caffeine · ORPHENADRINE CITRATE 50 mg/1; ASPIRIN 770 mg/1; CAFFEINE 60 mg/1 · Tablet · Oral · Atland Pharmaceuticals, LLC
NDC 71993-0307-60 · 60 TABLET in 1 BOTTLE, PLASTIC · ANDA · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Regulatory
- Application
- ANDA075141
- TE code
- —
- Approval date
- May 29, 1998
- Patents / exclusivity
- None on file
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of Orphenadrine Citrate, Aspirin and Caffeine (Tablet)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Atland Pharmaceuticals, LLC | ORPHENADRINE CITRATE 50 mg/1; ASPIRIN 770 mg/1; CAFFEINE 60 mg/1 | Aug 26, 2026 | Sep 2, 2026 |
| Atland Pharmaceuticals, LLC | ORPHENADRINE CITRATE 25 mg/1; ASPIRIN 385 mg/1; CAFFEINE 30 mg/1 | Aug 26, 2026 | Sep 2, 2026 |
| Galt Pharmaceuticals, LLC | ORPHENADRINE CITRATE 50 mg/1; ASPIRIN 770 mg/1; CAFFEINE 60 mg/1 | Aug 26, 2026 | Sep 2, 2026 |
| Galt Pharmaceuticals, LLC | ORPHENADRINE CITRATE 25 mg/1; ASPIRIN 385 mg/1; CAFFEINE 30 mg/1 | Aug 26, 2026 | Sep 2, 2026 |
| Atland Pharmaceuticals, LLC | ORPHENADRINE CITRATE 385 mg/1; ASPIRIN 30 mg/1; CAFFEINE 25 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| Atland Pharmaceuticals, LLC | ORPHENADRINE CITRATE 770 mg/1; ASPIRIN 60 mg/1; CAFFEINE 50 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| Galt Pharmaceuticals, LLC | ORPHENADRINE CITRATE 770 mg/1; ASPIRIN 60 mg/1; CAFFEINE 50 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| Galt Pharmaceuticals, LLC | ORPHENADRINE CITRATE 385 mg/1; ASPIRIN 30 mg/1; CAFFEINE 25 mg/1 | Jul 22, 2026 | Aug 19, 2026 |
| Atland Pharmaceuticals, LLC | ASPIRIN 770 mg/1; CAFFEINE 60 mg/1; ORPHENADRINE CITRATE 50 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
| Atland Pharmaceuticals, LLC | ASPIRIN 385 mg/1; CAFFEINE 30 mg/1; ORPHENADRINE CITRATE 25 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
| Galt Pharmaceuticals, LLC | ASPIRIN 770 mg/1; CAFFEINE 60 mg/1; ORPHENADRINE CITRATE 50 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
| Galt Pharmaceuticals, LLC | ASPIRIN 385 mg/1; CAFFEINE 30 mg/1; ORPHENADRINE CITRATE 25 mg/1 | Jul 15, 2026 | Jul 15, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Orphenadrine Citrate, Aspirin and Caffeine — NDC 71993-0307-60," retrieved September 3, 2026, https://drugdashboards.com/drug/71993030760.
Free to cite with attribution — see how the data is put together.